SEC Form 4 · accession 0001437749-26-028651
Eton Pharmaceuticals, Inc. · ETON
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sean Brynjelsen
Officer — President & CEO · Director
Period of report
Aug 19, 2026
Accepted (ET)
Aug 20, 2026 · 6:26 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001710340
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Aug 19, 2026 | S | 8,978 | $62.65 | D | 1,052,216 | D | |
| Common StockF2,F3 | Aug 20, 2026 | S | 47,307 | $60.17 | D | 1,004,909 | D | |
| Common StockF2,F4 | Aug 20, 2026 | S | 36,373 | $61.11 | D | 968,536 | D | |
| Common StockF2,F5 | Aug 20, 2026 | S | 7,342 | $62.12 | D | 961,194 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The shares were sold in multiple trades at prices ranging from $62.50 to $63.41. The price above reflects the weighted average sales price.
- F2The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F3The shares were sold in multiple trades at prices ranging from $59.59 to $60.59. The price above reflects the weighted average sales price.
- F4The shares were sold in multiple trades at prices ranging from $60.61 to $61.61. The price above reflects the weighted average sales price.
- F5The shares were sold in multiple trades at prices ranging from $61.63 to $62.52. The price above reflects the weighted average sales price.